Pharmacological Approach for Managing Pain in Irritable Bowel Syndrome: A Review Article
Open Access
- 25 January 2017
- journal article
- review article
- Published by Brieflands in Anesthesiology and Pain Medicine
- Vol. 7 (2) , e42747
Abstract
Context: Visceral pain is a leading symptom for patients with irritable bowel syndrome (IBS) that affects 10% - 20 % of the world population. Conventional pharmacological treatments to manage IBS-related visceral pain is unsatisfactory. Recently, medications have emerged to treat IBS patients by targeting the gastrointestinal (GI) tract and peripheral nerves to alleviate visceral pain while avoiding adverse effects on the central nervous system (CNS). Several investigational drugs for IBS also target the periphery with minimal CNS effects. Evidence of Acquisition: In this paper, reputable internet databases from 1960 - 2016 were searched including Pubmed and ClinicalTrials.org, and 97 original articles analyzed. Search was performed based on the following keywords and combinations: irritable bowel syndrome, clinical trial, pain, visceral pain, narcotics, opioid, chloride channel, neuropathy, primary afferent, intestine, microbiota, gut barrier, inflammation, diarrhea, constipation, serotonin, visceral hypersensitivity, nociceptor, sensitization, hyperalgesia. Results: Certain conventional pain managing drugs do not effectively improve IBS symptoms, including NSAIDs, acetaminophen, aspirin, and various narcotics. Anxiolytic and antidepressant drugs (Benzodiazepines, TCAs, SSRI and SNRI) can attenuate pain in IBS patients with relevant comorbidities. Clonidine, gabapentin and pregabalin can moderately improve IBS symptoms. Lubiprostone relieves constipation predominant IBS (IBS-C) while loperamide improves diarrhea predominant IBS (IBS-D). Alosetron, granisetron and ondansetron can generally treat pain in IBS-D patients, of which alosetron needs to be used with caution due to cardiovascular toxicity. The optimal drugs for managing pain in IBS-D and IBS-C appear to be eluxadoline and linaclotide, respectively, both of which target peripheral GI tract. Conclusions: Conventional pain managing drugs are in general not suitable for treating IBS pain. Medications that target the GI tract and peripheral nerves have better therapeutic profiles by limiting adverse CNS effects. Keywords: Irritable Bowel Syndrome; Clinical Trial; Visceral Pain; Visceral Hypersensitivity; Hyperalgesia; Diarrhea; ConstipationKeywords
This publication has 95 references indexed in Scilit:
- Development and Validation of the Rome IV Diagnostic Questionnaire for AdultsGastroenterology, 2016
- New pharmacological treatment options for irritable bowel syndrome with constipationExpert Opinion on Emerging Drugs, 2015
- Optimal management of constipation associated with irritable bowel syndromeTherapeutics and Clinical Risk Management, 2015
- Irritable Bowel Syndrome: Methods, Mechanisms, and Pathophysiology. Neural and neuro-immune mechanisms of visceral hypersensitivity in irritable bowel syndromeAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2012
- The Rome II and Rome III criteria identify the same subtype‐populations in irritable bowel syndrome: agreement depends on the method used for symptom reportNeurogastroenterology & Motility, 2012
- Childhood Trauma Is Associated With Hypothalamic-Pituitary-Adrenal Axis Responsiveness in Irritable Bowel SyndromeGastroenterology, 2009
- Genetics of Irritable Bowel SyndromeAmerican Journal of Gastroenterology, 2008
- Early Life Risk Factors That Contribute to Irritable Bowel Syndrome in Adults: A Systematic ReviewAmerican Journal of Gastroenterology, 2008
- Relationship of functional gastrointestinal disorders and psychiatric disorders: Implications for treatmentWorld Journal of Gastroenterology, 2007
- Functional Bowel DisordersGastroenterology, 2006